Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to
evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab
versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant
prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for
their prostate cancer disease.